TD Waterhouse Canada Inc. Sells 19,425 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

TD Waterhouse Canada Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,328 shares of the biopharmaceutical company's stock after selling 19,425 shares during the period. TD Waterhouse Canada Inc.'s holdings in Gilead Sciences were worth $5,017,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in GILD. HHM Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC increased its stake in shares of Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday. BMO Capital Markets upped their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Piper Sandler boosted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday. They issued an "overweight" rating and a $125.00 target price for the company. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $108.42.

Gilead Sciences Trading Down 2.8 %

Shares of GILD traded down $2.98 during trading hours on Friday, reaching $103.17. The stock had a trading volume of 14,207,970 shares, compared to its average volume of 7,556,748. The company has a market cap of $128.46 billion, a P/E ratio of 278.84, a P/E/G ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $119.96. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average of $109.26 and a 200 day moving average of $98.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.08. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 3.06%. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Tuesday, April 15th. The stock was sold at an average price of $106.40, for a total value of $266,000.00. Following the completion of the sale, the chief financial officer now directly owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 302,785 shares of company stock worth $30,540,875 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.